caption stringlengths 0 3.92k | molecule stringlengths 1 914 | properties listlengths 1 113 | additional_data dict |
|---|---|---|---|
The molecule is a energy source, a surfactant, and a stabilizing cytochrome oxidase, and it impacts barth syndrome. The molecule is a energy storage, food additive, nutritional supplement, apoptosis that impacts diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation and a emulsifier, impact... | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Barth syndrome",
"Energy source",
"surfactant",
"Stabilizing cytochrome oxidase",
"Energy storage",
"food additive",
"Nutritional supplement",
"Apoptosis",
"Diabetic heart disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Emulsifier",
"Non-alcoholic fatty liver dise... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory, nutrient, energy source that impacts obesity, metabolic syndrome, and pancreatitis. The molecule is a fat storage and membrane stabilizer, and it impacts atherosclerosis. The molecule is a energy storage that affects cancer by impacting both cardiovascular disease and thyroxine treatment... | CCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCCCCC | [
"inflammatory",
"nutrient",
"Obesity",
"Energy source",
"Metabolic syndrome",
"Pancreatitis",
"Fat storage",
"Membrane stabilizer",
"Atherosclerosis",
"Cardiovascular disease",
"Thyroxine treatment",
"Energy storage",
"Cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer and nutrient, belonging to the thyroxine treatment class of molecules, with effects on cancer and impacts on both cardiovascular disease and metabolic syndrome. The molecule is a energy storage and inflammatory, and it impacts atherosclerosis. The molecule is a energy source and a ... | CCC(C)CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCC(C)CC | [
"Thyroxine treatment",
"Cardiovascular disease",
"Cancer",
"Metabolic syndrome",
"Membrane stabilizer",
"nutrient",
"Atherosclerosis",
"Energy storage",
"inflammatory",
"Pancreatitis",
"Energy source",
"Fat storage",
"Obesity"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, cholesterol translocation that impacts diabetic heart disease and aging. The molecule is a apoptosis and a stabilizing mitochondrial structure that impacts barth syndrome, non-alcoholic fatty liver disease, and tangier disease. | CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Aging",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts alzheimer's disease, diabetes mellitus type 2, parkinson's disease, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCC[C@H](O)/C=C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OCCN | [
"nutrient",
"Alzheimer's Disease",
"Diabetes mellitus type 2",
"Parkinson's disease",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, tangier disease, and aging. The molecule is a cholesterol translocation, stabilizing mitochondrial structure, apoptosis that impacts non-alcoholic fatty liver disease and barth syndrome. | CCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC | [
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Aging",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source that affects breast cancer by impacting both cardiovascular disease and inflammatory bowel disease. It impacts renal cell carcinoma, heart failure, celiac disease, and diabetes mellitus type 2. | C[N+](C)(C)CC(CC(=O)[O-])OC(=O)CCCC(O)CCCCCCCCCCC(=O)O | [
"Energy source",
"Cardiovascular disease",
"Breast cancer",
"Inflammatory bowel disease",
"Renal cell carcinoma",
"Heart failure",
"Celiac disease",
"Diabetes mellitus type 2"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CC1C(=O)C2(COC3OC(CO)C(O)C(O)C3O)CCC1C2 | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti inflammatory. | CCCOc1cccc(-n2nnnc2C(F)(F)F)c1 | [
"anti inflammatory"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts aging, non-alcoholic fatty liver disease, and diabetic heart disease. The molecule is a apoptosis, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts tangier disease and barth syndrome. | CC(C)CCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C | [
"Stabilizing cytochrome oxidase",
"Aging",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Cholesterol translocation",
"Tangier disease",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts diabetic heart disease, barth syndrome, and tangier disease. The molecule is a apoptosis, proton trap for oxidative phosphorylation, cholesterol translocation that impacts non-alcoholic fatty liver disease and aging. | CC(C)CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC(C)C | [
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Aging",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory, nutrient, energy source, and energy storage, impacts metabolic syndrome, and is thyroxine treatment. The molecule is a membrane stabilizer that impacts both pancreatitis and obesity. The molecule is a fat storage that affects cancer by impacting both cardiovascular disease and atheroscle... | CCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCC(C)C | [
"Thyroxine treatment",
"inflammatory",
"nutrient",
"Energy source",
"Metabolic syndrome",
"Energy storage",
"Membrane stabilizer",
"Pancreatitis",
"Obesity",
"Cardiovascular disease",
"Atherosclerosis",
"Cancer",
"Fat storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts thyroxine treatment, cardiovascular disease, and pancreatitis. The molecule is a nutrient and a fat storage, impacting both atherosclerosis and metabolic syndrome. | CCCCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCC | [
"Thyroxine treatment",
"Cardiovascular disease",
"Pancreatitis",
"nutrient",
"Atherosclerosis",
"Fat storage",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, apoptosis, stabilizing cytochrome oxidase, energy source. The molecule is a proton trap for oxidative phosphorylation, a nutritional supplement, and a cholesterol translocation, it impacts aging and is smooth. The molecule is a energy storage and a emulsifier, impacting both tangi... | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\CCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Membrane stabilizer",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Energy source",
"Proton trap for oxidative phosphorylation",
"Nutritional supplement",
"Aging",
"Cholesterol translocation",
"Smooth",
"Energy storage",
"Emulsifier",
"Tangier disease",
"Barth syndrome",
"Non-alcoholic ... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts non-alcoholic fatty liver disease, diabetic heart disease, and aging. The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, stabilizing mitochondrial structure that impacts tangier disease and barth syndrome. | CCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCC(C)C | [
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Apoptosis",
"Aging",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Barth syndrome",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, a surfactant, and a proton trap for oxidative phosphorylation, and it impacts barth syndrome. The molecule is a emulsifier, stabilizing cytochrome oxidase, energy storage, nutritional supplement that impacts tangier disease. The molecule is a energy source and a food additiv... | CCCCCC/C=C\C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC(C)CC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C | [
"Barth syndrome",
"Cholesterol translocation",
"surfactant",
"Proton trap for oxidative phosphorylation",
"Emulsifier",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Energy storage",
"Nutritional supplement",
"Aging",
"Energy source",
"food additive",
"Diabetic heart disease",
"Apo... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a cholesterol translocation that impacts tangier disease, aging, and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts barth syndrome and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCCCCC(C)C | [
"Apoptosis",
"Cholesterol translocation",
"Tangier disease",
"Aging",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both atherosclerosis and cardiovascular disease. The molecule is a fat storage and a thyroxine treatment, impacting both pancreatitis and metabolic syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCC | [
"Atherosclerosis",
"nutrient",
"Cardiovascular disease",
"Fat storage",
"Pancreatitis",
"Metabolic syndrome",
"Thyroxine treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a surfactant, membrane stabilizer, emulsifier, energy storage. The molecule is a energy source and a nutrient, as well as minty and vanilla. | CSCSCSC | [
"surfactant",
"Membrane stabilizer",
"Emulsifier",
"Energy storage",
"minty",
"vanilla",
"Energy source",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis that impacts barth syndrome, non-alcoholic fatty liver disease, aging, and tangier disease. The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, stabilizing cytochrome oxidase that impacts diabetic heart disease. | CCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)CC | [
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Aging",
"Tangier disease",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts tangier disease, aging, and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, apoptosis, stabilizing mitochondrial structure that impacts diabetic heart disease and barth syndrome. | CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCC | [
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Aging",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Cholesterol translocation",
"Apoptosis",
"Barth syndrome",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage, membrane stabilizer, energy source that belongs to the thyroxine treatment class of molecules and impacts both cardiovascular disease and pancreatitis. The molecule is a inflammatory and energy storage, and it impacts cancer. The molecule is a nutrient that impacts atherosclerosis, obesit... | CCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)CC | [
"Cardiovascular disease",
"Pancreatitis",
"Fat storage",
"Membrane stabilizer",
"Energy source",
"Thyroxine treatment",
"Cancer",
"inflammatory",
"Energy storage",
"Atherosclerosis",
"nutrient",
"Obesity",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](N)C(=O)O)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CC(O)CCC | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage and belongs to the thyroxine treatment class of molecules, impacting atherosclerosis. The molecule is a nutrient that impacts metabolic syndrome, pancreatitis, and cardiovascular disease. | CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)OC[C@@H](COCCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCC/C=C\C/C=C\CCCCC | [
"Fat storage",
"Atherosclerosis",
"Thyroxine treatment",
"Metabolic syndrome",
"nutrient",
"Pancreatitis",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory, energy source, nutrient that impacts obesity, atherosclerosis, and pancreatitis. The molecule is a membrane stabilizer and energy storage with an effect on cancer. The molecule is a fat storage that impacts metabolic syndrome, thyroxine treatment, and cardiovascular disease. | CCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | [
"inflammatory",
"Energy source",
"nutrient",
"Obesity",
"Atherosclerosis",
"Pancreatitis",
"Cancer",
"Membrane stabilizer",
"Energy storage",
"Metabolic syndrome",
"Thyroxine treatment",
"Fat storage",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source, membrane stabilizer, surfactant, emulsifier, nutrient, energy storage. | COc1ccc(-c2cc(=O)c3c(O)cc(O)c(OC4OC(CO)C(O)C(O)C4OS(=O)(=O)O)c3o2)cc1 | [
"Energy source",
"Membrane stabilizer",
"surfactant",
"Emulsifier",
"nutrient",
"Energy storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cdk inhibitor and is cancer treatment. | Nc1nc(NC2CC3CCC2C3)sc1C(=O)c1ccc([N+](=O)[O-])cc1 | [
"cdk inhibitor",
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | O=c1oc2cc(O)ccc2c2oc3cc(O)cc(O)c3c12 | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer and a stabilizing cytochrome oxidase, it impacts aging, and is smooth. The molecule is a apoptosis, proton trap for oxidative phosphorylation, emulsifier that impacts tangier disease and diabetic heart disease. The molecule is a food additive, a energy storage, and a nutritional su... | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Smooth",
"Aging",
"Membrane stabilizer",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Diabetic heart disease",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Emulsifier",
"Barth syndrome",
"food additive",
"Energy storage",
"Nutritional supplement",
"surfactant",
"E... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a energy storage, impacting both diabetic heart disease and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, a stabilizing cytochrome oxidase, and a energy source, it impacts aging and is smooth. The molecule is a apoptosis, ... | CC(C)CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCC(C)C | [
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Energy storage",
"Cholesterol translocation",
"Aging",
"Stabilizing cytochrome oxidase",
"Smooth",
"Energy source",
"Apoptosis",
"Tangier disease",
"food additive",
"Emulsifier",
"N... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a lpxc inhibitor and is anti bacterial. | CC(O)(C(F)F)C(NC(=O)c1ccc(C#CC#Cc2ccc(NS(C)(=O)=O)cc2)cc1)C(=O)NO | [
"anti bacterial",
"lpxc inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a bromodomain inhibitor and is tumor treatment. | BrCc1ccc(C=C2CCC2)c(Br)c1 | [
"bromodomain inhibitor",
"tumor treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage and thyroxine treatment, and it impacts cardiovascular disease. The molecule is a nutrient that impacts pancreatitis, metabolic syndrome, and atherosclerosis. | CCCCCCCC/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC/C=C\CCCCCCCC | [
"Thyroxine treatment",
"Fat storage",
"Cardiovascular disease",
"Pancreatitis",
"Metabolic syndrome",
"nutrient",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is anti fungal. | Clc1ccc(C(OCc2coc3c(Cl)cc(Cl)cc23)C(Cl)n2ccnc2)cc1 | [
"anti fungal"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, barth syndrome, and tangier disease. The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, proton trap for oxidative phosphorylation that impacts diabetic heart disease and aging. | CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)CC | [
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts alzheimer's disease, parkinson's disease, non-alcoholic fatty liver disease, and diabetes mellitus type 2. | CCCCCCCC/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCC(O)/C=C/C=C/C/C=C/CCCCCCCC | [
"nutrient",
"Alzheimer's Disease",
"Parkinson's disease",
"Non-alcoholic fatty liver disease",
"Diabetes mellitus type 2"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, fat storage, energy storage that impacts cancer, metabolic syndrome, and pancreatitis. The molecule is a energy source that impacts both atherosclerosis and obesity. The molecule is a nutrient and a inflammatory, impacting both cardiovascular disease and thyroxine treatment. | CCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCC(C)C | [
"Membrane stabilizer",
"Cancer",
"Metabolic syndrome",
"Pancreatitis",
"Fat storage",
"Energy storage",
"Atherosclerosis",
"Energy source",
"Obesity",
"nutrient",
"inflammatory",
"Cardiovascular disease",
"Thyroxine treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a phosphodiesterase inhibitor and a pde4 inhibitor, which impacts both copd treatment and allergic disease treatment, and is characterized as inflammatory disease treatment. | CCn1ncc2c(NC3CCC(=NO)CC3)c(C(=O)NC(C)c3cc(C)cc(C)c3)cnc21 | [
"phosphodiesterase inhibitor",
"COPD treatment",
"allergic disease treatment",
"inflammatory disease treatment",
"pde4 inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, energy source, energy storage, membrane stabilizer that has an effect on cancer and impacts atherosclerosis. The molecule is a fat storage that impacts both metabolic syndrome and pancreatitis. The molecule is a thyroxine treatment and a inflammatory, impacting both obesity and cardiovascula... | CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)CC | [
"nutrient",
"Energy source",
"Energy storage",
"Cancer",
"Atherosclerosis",
"Membrane stabilizer",
"Fat storage",
"Metabolic syndrome",
"Pancreatitis",
"Obesity",
"Thyroxine treatment",
"inflammatory",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti thrombotic class of molecules. | Br.Br.CCN1CCc2cc(N)sc2CC1 | [
"anti thrombotic"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a lipoxygenase inhibitor, which belongs to the pesticide class of molecules, and is choleretic, sweet, and anti inflammatory. The molecule is a flavor and vermifuge, belonging to the herbicide class, and is characterized as cinnamon, balsam, and anti mutagenic. The molecule is a anti spasmodic and aller... | O=C(O)/C=C\c1ccccc1 | [
"choleretic",
"sweet",
"lipoxygenase inhibitor",
"pesticide",
"anti inflammatory",
"cinnamon",
"flavor",
"balsam",
"anti mutagenic",
"vermifuge",
"herbicide",
"anti spasmodic",
"allergen",
"dermatitigenic",
"anesthetic",
"storax",
"fungicide",
"EC 1.14.18.1 (tyrosinase) inhibitor",... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a phosphodiesterase inhibitor, anti leukemic, anti tnf, immunological adjuvant. The molecule is a anti topoisomerase-ii and cytotoxic, belonging to both the anti viral agent and anti tumor classes of molecules. The molecule is a topoisomerase inhibitor and a anti hiv, as well as anti proliferant and ant... | CC1=CC(C/C(C)=C\COc2c3occc3cc3ccc(=O)oc23)OC1=O | [
"phosphodiesterase inhibitor",
"anti leukemic",
"anti TNF",
"immunological adjuvant",
"anti viral agent",
"anti topoisomerase-II",
"cytotoxic",
"anti tumor",
"topoisomerase inhibitor",
"anti proliferant",
"anti lymphomic",
"anti HIV",
"anti integrase",
"differentiator",
"immunomodulator"... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a betasecretase inhibitor and a alzheimer's treatment. | COC(=O)c1cc(OCC(=O)NCCCCCC=O)cc(C(=O)OC)c1 | [
"betasecretase inhibitor",
"alzheimer's treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, apoptosis, stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease and aging. The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts barth syndrome, diabetic heart disease, and tangier disease. | CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | [
"Stabilizing mitochondrial structure",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Aging",
"Barth syndrome",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a cancer treatment and a adenosine receptor antagonist. | Cc1cc(-c2c(-c3ccccc3)nc(N)n3c(=O)n(Cc4ccc(F)cn4)nc23)cc(N2CCC2)n1 | [
"cancer treatment",
"adenosine receptor antagonist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts diabetic heart disease and aging. The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts non-alcoholic fatty liver disease, barth syndrome, and tangier disease. | CCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCC(C)C | [
"Cholesterol translocation",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Aging",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Apoptosis",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | COc1cc(/C=C/C(=O)OCC2OC(OC3C(c4c(OC)cc5oc(-c6ccc(O)cc6)cc(=O)c5c4O)OC(CO)C(O)C3O)C(O)C(O)C2O)cc(OC)c1O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts cancer treatment. | COC1CC(Nc2cc(-c3cccc(NCC4(N)CCOCC4)n3)c(Cl)cn2)CCC1N | [
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, apoptosis that impacts tangier disease and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts aging, barth syndrome, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Tangier disease",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Apoptosis",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Aging",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, diabetic heart disease, barth syndrome, and aging. The molecule is a stabilizing cytochrome oxidase, apoptosis, cholesterol translocation, proton trap for oxidative phosphorylation that impacts tangier disease. | CCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Aging",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source that affects breast cancer by impacting both heart failure and cardiovascular disease. It impacts inflammatory bowel disease, celiac disease, diabetes mellitus type 2, and renal cell carcinoma. | CCCCC=CCC(O)CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C | [
"Breast cancer",
"Heart failure",
"Energy source",
"Cardiovascular disease",
"Inflammatory bowel disease",
"Celiac disease",
"Diabetes mellitus type 2",
"Renal cell carcinoma"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts tangier disease and non-alcoholic fatty liver disease. The molecule is a apoptosis and a cholesterol translocation that impacts aging, diabetic heart disease, and barth syndrome. | CCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC | [
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Aging",
"Apoptosis",
"Diabetic heart disease",
"Barth syndrome",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a protein kinase inhibitor. | Cc1cc2c(cn1)cc(-c1cc(NC(=O)c3c(C)c(C)c(C)n3C)ccc1C)c(=O)n2C | [
"protein kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a laboratory chemical and a food and nutrition, is diuretic, and has a Distinctive ethereal odor, somewhat like peppermint. | O=C1CCCC1 | [
"Laboratory chemical",
"Odor_evaluation",
"diuretic",
"Food and nutrition"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a energy source, it impacts barth syndrome, and is smooth. The molecule is a stabilizing mitochondrial structure, food additive, emulsifier, nutritional supplement that impacts aging. The molecule is a membrane stabilizer that impacts diabetic heart disease, tangier ... | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Smooth",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Energy source",
"Stabilizing mitochondrial structure",
"food additive",
"Emulsifier",
"Aging",
"Nutritional supplement",
"Diabetic heart disease",
"Membrane stabilizer",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation that impacts aging, barth syndrome, non-alcoholic fatty liver disease, and tangier disease. The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, apoptosis, stabilizing mitochondrial structure that impacts diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Aging",
"Barth syndrome",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts tangier disease and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts non-alcoholic fatty liver disease, aging, and barth syndrome. | CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCCCCC | [
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Aging",
"Cholesterol translocation",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts barth syndrome and diabetic heart disease. The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts tangier disease, non-alcoholic fatty liver disease, and aging. | CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)CC | [
"Barth syndrome",
"Diabetic heart disease",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation that impacts tangier disease, diabetic heart disease, non-alcoholic fatty liver disease, and barth syndrome. The molecule is a apoptosis, cholesterol translocation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts aging. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC | [
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Apoptosis",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a proton trap for oxidative phosphorylation that impacts barth syndrome, diabetic heart disease, and tangier disease. The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, apoptosis that impacts non-alcoholic fatty liver disease and aging. | CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCC(C)CC | [
"Barth syndrome",
"Diabetic heart disease",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Aging",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, apoptosis, stabilizing cytochrome oxidase that impacts aging. The molecule is a proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease, diabetic heart disease, barth syndrome, and tangier disease. | CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC(C)C | [
"Stabilizing mitochondrial structure",
"Aging",
"Cholesterol translocation",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Barth syndrome",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on colorectal cancer, and impacts alzheimer's disease, parkinson's disease, and cardiovascular disease. It influences both stomach cancer and breast cancer, as well as affecting seizure and diabetes mellitus. | CC/C=C\C/C=C\C/C=C\C/C=C\C=C\C(O)CCCC(=O)OC[C@H](COP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O)OC(=O)CCCCCC/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Alzheimer's Disease",
"Parkinson's disease",
"Colorectal cancer",
"Cardiovascular disease",
"Stomach cancer",
"Seizure",
"Breast cancer",
"Diabetes mellitus"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that affects breast cancer by impacting ulcerative colitis, atherosclerosis, and cervical cancer. | CCCCCC/C=C\C/C=C\C/C=C\CCCCCCCCC(=O)O[C@H](COC(=O)CCCCCC[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]1O)COP(=O)([O-])OCC[N+](C)(C)C | [
"Ulcerative colitis",
"Atherosclerosis",
"Breast cancer",
"Cervical cancer",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, oily, herbal, earthy, herb. | CC1CCC2(OC1)OC1CC3C4CCC5CC(OC6OC(COC7OC(CO)C(O)C(O)C7O)C(OC7OC(C)C(O)C(O)C7O)C(O)C6OC6OC(CO)C(O)C(O)C6O)CCC5(C)C4CCC3(C)C1C2C | [
"oily",
"herbal",
"earthy",
"nutrient",
"herb"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a metalloproteinase inhibitor. | CCCCOC(=O)NC(CC(=O)NC(C(=O)NC)C(C)(C)C)C(=O)OCc1ccccc1 | [
"metalloproteinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase that impacts tangier disease, non-alcoholic fatty liver disease, aging, and barth syndrome. The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, apoptosis, stabilizing mitochondrial structure that impacts diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Aging",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing cytochrome oxidase, cholesterol translocation, stabilizing mitochondrial structure that impacts diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation that impacts aging, non-alcoholic fatty liver disease, tangier disease, and barth syndrome. | CCC(C)CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)CC | [
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Aging",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutritional supplement that impacts non-alcoholic fatty liver disease, barth syndrome, and aging. The molecule is a membrane stabilizer, stabilizing cytochrome oxidase, emulsifier that impacts diabetic heart disease and tangier disease. The molecule is a proton trap for oxidative phosphorylation, a en... | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Nutritional supplement",
"Aging",
"Membrane stabilizer",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Emulsifier",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Energy storage",
"Smooth",
"Energy sourc... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is anti microbial. | CC(C)(C)NC(=O)NC1CCN(CCCN)C1 | [
"anti microbial"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts inflammation treatment. | Cc1cc(OCC(F)=CCN)ccc1S(C)(=O)=O | [
"inflammation treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage, fat storage, inflammatory, nutrient that impacts atherosclerosis and obesity. The molecule is a thyroxine treatment that impacts both metabolic syndrome and pancreatitis. The molecule is a energy source and a membrane stabilizer, impacting both cardiovascular disease and cancer. | CCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCC(C)C | [
"Energy storage",
"Atherosclerosis",
"Obesity",
"Fat storage",
"inflammatory",
"nutrient",
"Metabolic syndrome",
"Pancreatitis",
"Thyroxine treatment",
"Energy source",
"Cardiovascular disease",
"Cancer",
"Membrane stabilizer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both metabolic syndrome and pancreatitis. The molecule is a fat storage that impacts atherosclerosis, cardiovascular disease, and thyroxine treatment. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCC | [
"Metabolic syndrome",
"nutrient",
"Pancreatitis",
"Atherosclerosis",
"Cardiovascular disease",
"Thyroxine treatment",
"Fat storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, tangier disease, and barth syndrome. The molecule is a stabilizing cytochrome oxidase, apoptosis, cholesterol translocation that impacts aging and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Barth syndrome",
"Aging",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a organic electroluminescent device and is electroluminescent. | c1ccc(-c2ccc(-c3cc(C4=Nc5ccc(-c6ccccc6)cc5C(c5ccccc5)N4)cc(-c4ccc(-c5ncccn5)cc4)c3)cc2)cc1 | [
"electroluminescent",
"organic electroluminescent device"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is cancer treatment. | CC(C)C(Nc1nc(CNC(=O)Nc2ccccc2Cl)nc2ccccc12)C(N)=O | [
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source and a membrane stabilizer, impacting both tangier disease and diabetic heart disease. The molecule is a apoptosis, stabilizing mitochondrial structure, surfactant, stabilizing cytochrome oxidase that impacts barth syndrome. The molecule is a proton trap for oxidative phosphorylation, a c... | CCC(C)CCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Energy source",
"Membrane stabilizer",
"Tangier disease",
"Diabetic heart disease",
"Barth syndrome",
"Apoptosis",
"Stabilizing mitochondrial structure",
"surfactant",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Non-alcoholic fa... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a cathepsin inhibitor and a cathepsin s inhibitor. | N#CC1(NC(=O)C(CS(=O)(=O)Cc2ccccc2)OC(=O)N2CCOCC2)CCOCC1 | [
"cathepsin inhibitor",
"cathepsin s inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cysteine protease inhibitor and is anti malarial. | CC(C)CN(NC(=O)c1ccc(CN2CCCCC2)cc1)c1nc(C#N)ncc1Cl | [
"anti malarial",
"cysteine protease inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that affects both breast cancer and cervical cancer, and also impacts atherosclerosis and ulcerative colitis. | CCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C=C\C(=O)CCCCC)COP(=O)([O-])OCC[N+](C)(C)C | [
"Breast cancer",
"Atherosclerosis",
"Cervical cancer",
"nutrient",
"Ulcerative colitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation that impacts non-alcoholic fatty liver disease, aging, tangier disease, and barth syndrome. The molecule is a apoptosis, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts diabetic heart disease. | CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC | [
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Aging",
"Tangier disease",
"Barth syndrome",
"Apoptosis",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti microbial. | C#CCn1nnnc1SCC1=C(C(=O)O)N2C(=O)C(NC(=O)CSCC=C)C2SC1 | [
"anti microbial"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, apoptosis, cholesterol translocation that impacts diabetic heart disease and aging. The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, tangier disease, and barth syndrome. | CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Cholesterol translocation",
"Aging",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cancer treatment. | CC(C)(C)OC(=O)NC(COc1cnc(-c2ccccc2)c(-c2ccc3c(c2)c(N=C(c2ccccc2)c2ccccc2)nn3C(=O)OC(C)(C)C)c1)Cc1ccccc1 | [
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti allergy member of the anti allergic class. | O=C1Cc2ccccc2C(=C2CCN(Cc3ccncc3)CC2)c2ccsc21 | [
"anti allergy",
"anti allergic"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cell cycle inhibitor and belongs to the cancer treatment class of molecules. | CCC(C)n1c2cnccc2c2cnc(Nc3ccc(N4CCC(NC)CC4)nn3)nc21 | [
"cell cycle inhibitor",
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts pancreatitis, metabolic syndrome, and atherosclerosis. The molecule is a thyroxine treatment, a nutrient, and a fat storage, and it impacts cardiovascular disease. | CCCC/C=C\CCCCCCCC(=O)OC[C@@H](COCCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Pancreatitis",
"Metabolic syndrome",
"Atherosclerosis",
"Thyroxine treatment",
"nutrient",
"Cardiovascular disease",
"Fat storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cancer treatment, a pain treatment, and a faah inhibitor, belonging to the anti malarial class of molecules and is fibrosis treatment. | CC1=CC=CC(F)C1 | [
"cancer treatment",
"pain treatment",
"faah inhibitor",
"anti malarial",
"fibrosis treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fungicide and flavor, belonging to the amphetaminagenic class of molecules, and is anti oxidant. The molecule is a sedative and a calcium channel blocker, it impacts euphoria, and is warm. The molecule is a oxytocic and utero tonic, balsamic, and has an effect on cancer preventive. The molecule is a h... | Cc1cc(O)cc(O)c1C(=O)OC1CC2(C)C3C(O)C(C)(C)CC3(O)C=C(C=O)C12O | [
"fungicide",
"flavor",
"amphetaminagenic",
"anti oxidant",
"warm",
"Euphoria",
"sedative",
"calcium channel blocker",
"balsamic",
"oxytocic",
"cancer preventive",
"utero tonic",
"hepatotoxic agent",
"hepatoprotective",
"psychoactive",
"pesticide",
"anti inflammatory",
"hallucinogen... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti viral. | CCCOc1ccc(-c2ncc(C(C(=O)OCCC(=O)NC(C)C(=O)O)n3cc4nc(-c5cccc(F)c5F)nc-4cn3)cn2)c(C(F)(F)F)c1 | [
"anti viral"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease and diabetic heart disease. The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts barth syndrome, aging, and tangier disease. | CCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)CC | [
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Apoptosis",
"Aging",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts aging, barth syndrome, and tangier disease. The molecule is a cholesterol translocation, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease and diabetic heart disease. | CCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCC(C)C | [
"Aging",
"Barth syndrome",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts diabetes mellitus type 2, non-alcoholic fatty liver disease, parkinson's disease, and alzheimer's disease. | CC/C=C\C(O)C/C=C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OCCN | [
"nutrient",
"Diabetes mellitus type 2",
"Non-alcoholic fatty liver disease",
"Parkinson's disease",
"Alzheimer's Disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, apoptosis that impacts tangier disease and barth syndrome. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, aging, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Stabilizing mitochondrial structure",
"Tangier disease",
"Barth syndrome",
"Cholesterol translocation",
"Apoptosis",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Aging",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, energy source, energy storage that impacts confusion and vomiting. The molecule is a air pollutant, nutrient, environmental contaminant that impacts nausea and dizziness. | CCC/C=C/CCCCCC | [
"Membrane stabilizer",
"Confusion",
"Energy source",
"Energy storage",
"Vomiting",
"Air pollutant",
"nutrient",
"Nausea",
"Dizziness",
"environmental contaminant"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, cholesterol translocation that impacts barth syndrome and aging. The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts diabetic heart disease, non-alcoholic fatty liver disease, and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Aging",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a cholesterol translocation that impacts non-alcoholic fatty liver disease, barth syndrome, and aging. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, stabilizing cytochrome oxidase that impacts diabetic heart disease and tangier disease. | CCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC(C)C | [
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Apoptosis",
"Cholesterol translocation",
"Aging",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Tangier disease",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts barth syndrome and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation and a apoptosis that impacts tangier disease, diabetic heart disease, and aging. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Diabetic heart disease",
"Cholesterol translocation",
"Apoptosis",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, cholesterol translocation that impacts aging. The molecule is a apoptosis that impacts diabetic heart disease, non-alcoholic fatty liver disease, barth syndrome, and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCC | [
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Aging",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Barth syndrome",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on breast cancer, and impacts alzheimer's disease, parkinson's disease, and diabetes mellitus. It has an effect on colorectal cancer, and impacts cardiovascular disease, stomach cancer, and seizure. | CCCCC/C=C\C/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCC[C@@H](O)[C@H](O)C/C=C\CCCCC)COP(=O)(O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(=O)(O)O)C1O | [
"Alzheimer's Disease",
"Parkinson's disease",
"Diabetes mellitus",
"Breast cancer",
"Cardiovascular disease",
"Stomach cancer",
"Colorectal cancer",
"Seizure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti obesity class of molecules. | CC(C)(C)OC(=O)N1Cc2ccccc2CC1C(=O)NC(Cc1ccc(Cl)cc1)C(=O)N1CCC(c2ccccc2C(F)(F)F)CC1 | [
"anti obesity"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.